According to Goldstein Research, increasing novel drug treatment, ease to purchase, ongoing innovations and developments in vaccine and high adoption and acceptance in developing market are the driving factors of global dengue vaccine market.
Global dengue vaccine market has been classified on the basis of technology and end users. Among end users government institutes dominate the global dengue vaccine market followed by hospitals, labs and NGO’s. Global dengue vaccine market valued USD 0.22 billion in 2016 and is expected to reach USD 1.15 by 2024 at a CAGR of 17% over the forecast period.
Brazil and Mexico are anticipated to be leading contributors to the dengue vaccine market, estimated to be around USD 0.08 billion in 2016 to USD 0.5 billion by 2024 and grow at a compound annual growth rate (CAGR) of 40% followed by India, Singapore and Thailand.
Future Directions in Dengue Vaccines
According to the World Health Organisation, dengue infects around 400 million people across 128 countries and kills 22,000 people annually. Due to lack of specific therapeutics and prevention in dengue which is currently limited to vector control measures. Buildout tetravalent dengue vaccine is considered as a high public health priority. ICGEB is partnering with Sun Pharma for research and development of an injectible vaccine that prevents against all four dengue strains that are endemic to India.
“Global Dengue Vaccine Market 2024” contains detailed overview of the global dengue vaccine market in terms of market segmentation by technology end user and geographies.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis.
Global dengue vaccine market also provides competitive outlook of some of the major players of the global dengue vaccine market which includes profiling of companies such as Sanofi Pasteur, Panacea Biotec, Biological E. Limited, GlaxoSmithKline plc, Merck & Co., Inc. and Takeda Pharmaceutical Company Ltd. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.
Overall, the report represents comprehensive synopsis on the global dengue vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear cut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.